Mould Illness

Indoor dampness and mould have a solid, boring, regulatory-grade evidence base: WHO's indoor air quality guidelines and successive systematic reviews link damp, mouldy housing to asthma development and exacerbation, respiratory infections, wheeze and rhinitis — effects large enough that remediation trials improve asthma outcomes and that damp housing is treated as a health hazard in housing law, a point made brutally concrete by the 2020 death of two-year-old Awaab Ishak from prolonged mould exposure in UK social housing, which produced legislation in his name. Allergic mechanisms (sensitisation to mould spores), irritant effects and infection risk in the immunocompromised (invasive aspergillosis) are all established medicine. Nobody serious disputes any of this — and this settled half is what the contested half borrows its plausibility from.

The parallel claim system — toxic mould illness, chronic inflammatory response syndrome (CIRS), mycotoxin toxicity — asserts that indoor mould exposure causes multi-system illness far beyond the airways: chronic fatigue, cognitive dysfunction, pain, mood disorder and dozens of listed symptoms, diagnosed via urine mycotoxin testing and proprietary marker panels, treated with binders (cholestyramine), antifungals, extreme avoidance protocols and supplement regimens. The mainstream assessment is blunt: professional allergy and occupational-medicine bodies have reviewed the evidence and found the toxicity syndrome unsupported at building-exposure levels — mycotoxins are real poisons at agricultural and food doses, but inhaled indoor exposures are orders of magnitude below toxic thresholds, the symptom lists are unfalsifiably broad, and the diagnostic tests fail validation. The settled respiratory harms and the contested systemic syndrome are different claims, and the industry's core move is to blur them.

The commercial pipeline runs through laboratories offering urine mycotoxin panels — tests that professional allergy societies explicitly recommend against, because mycotoxins are detectable in the urine of healthy people from ordinary diet (coffee, grains, nuts carry trace mycotoxins), reference ranges are not established for distinguishing illness, and results do not correlate with building exposure or symptoms. CIRS adds proprietary biomarker batteries (visual contrast testing, genetic susceptibility claims via HLA typing, marker panels) whose diagnostic performance has never been validated in controlled studies. The output pattern matches the chronic-Lyme playbook hub-for-hub: tests that overwhelmingly return positives, a diagnosis that explains any symptom, treatments that never conclude — and patients whose actual conditions (sleep apnoea, depression, autoimmune disease, ME/CFS-pattern illness) go unaddressed while they relocate homes and buy protocols.

The movement's fuel is familiar from every contested-syndrome hub: genuinely ill people with normal standard tests, medical encounters that ended in dismissal, and an ecosystem offering belief plus mechanism plus plan. But mould illness adds two honest complications. First, buildings really do make some people sick — damp-building respiratory disease is settled, some occupants have genuine mould allergy, and building-related symptom clusters (historically labelled sick building syndrome) are documented even where mechanisms stay murky; a person who improves away from a damp home is not imagining it, and allergy plus irritant load explains many such cases without any toxin theory. Second, dampness associates with mental-health effects through entirely mundane pathways — stress, cold, housing insecurity, disrupted sleep. The evidence-based response takes the building seriously and fixes it; the industry's response takes the fear seriously and monetises it.

The CIRS pathway is not a harmless alternative narrative. Documented costs include: five-figure diagnostic and treatment protocols outside any insurance rationale; families abandoning homes and possessions under extreme-avoidance instruction — a life-dismantling intervention prescribed on unvalidated tests; children subjected to restrictive regimes and school withdrawal; nocebo amplification, in which catastrophic framing of any mould sighting generates symptom vigilance (the placebo-and-nocebo hub's machinery, running at household scale); missed treatable diagnoses; and litigation and remediation economies with strong incentives to inflate. Meanwhile the boring, effective interventions — fixing leaks, ventilation, dehumidification, landlord accountability — are cheap, evidence-based, and beneficial regardless of which theory anyone holds, which makes their neglect in favour of binder protocols the clearest measure of the industry's priorities.

If your home is damp or mouldy: fix the water problem — leaks, ventilation, humidity below ~50-60%, prompt drying after events; small areas are a DIY clean, large or recurring contamination needs professional source-focused remediation, and tenants have enforceable rights in many jurisdictions (explicitly including post-Awaab UK social housing). If you have respiratory symptoms in a damp building: that is the settled territory — see a clinician, treat the asthma or allergy, and pursue the building fix as part of the prescription. If you have been offered urine mycotoxin testing or a CIRS protocol for fatigue and brain fog: decline, and invest the same energy in a real differential — sleep, thyroid, mental health, autoimmune screening and, where it fits, the post-acute syndrome pathway. And if you are immunocompromised: mouldy environments carry genuine infection risk for you specifically — avoidance there is standard medicine, not the industry's theatre.